Texas Roadhouse earnings missed by $0.05, revenue topped estimates
The analyst's commentary reflects careful consideration of Haleon's latest guidance and market conditions, particularly the influence of currency exchange rates. Kawan's updated price target for Haleon's American Depositary Receipts (ADRs) considers the recent movements in the GBP/USD exchange rates since their last update. The price target for Haleon's stock listed in Great Britain remains at 410 pence. Based on InvestingPro's Fair Value analysis, Haleon appears to be trading near its fair value, with analyst targets ranging from $9.50 to $11.41. Based on InvestingPro's Fair Value analysis, Haleon appears to be trading near its fair value, with analyst targets ranging from $9.50 to $11.41.
Kawan's analysis indicates that Haleon is projected to achieve a fourth-quarter organic sales growth (OSG) of 6.2%, which aligns with the consensus. For the full year 2024, the OSG expectation is slightly lower at 4.8%. Despite these consistent sales growth projections, Morgan Stanley (NYSE:MS) has revised its margin forecasts downward due to the impact of recent mergers and acquisitions and foreign exchange (FX) dilution guidance from Haleon. The new estimate for the company's EBIT margins is 22.3%, a slight decrease from the prior estimate of 22.6% and marginally below the consensus of 22.5%.
For the fiscal year 2025, the firm continues to forecast an OSG of 5.0%, which remains steady and is in line with previous estimates, albeit slightly lower than the consensus of 5.2%. The anticipated EBIT margins for FY25 have also been adjusted to 22.6%, down from the earlier projection of 22.8% but still above the consensus of 22.7%.
The analyst's commentary reflects careful consideration of Haleon's latest guidance and market conditions, particularly the influence of currency exchange rates. Kawan's updated price target for Haleon's American Depositary Receipts (ADRs) considers the recent movements in the GBP/USD exchange rates since their last update. The price target for Haleon's stock listed in Great Britain remains at 410 pence. Based on InvestingPro's Fair Value analysis, Haleon appears to be trading near its fair value, with analyst targets ranging from $9.50 to $11.41.
The analyst's commentary reflects careful consideration of Haleon's latest guidance and market conditions, particularly the influence of currency exchange rates. Kawan's updated price target for Haleon's American Depositary Receipts (ADRs) considers the recent movements in the GBP/USD exchange rates since their last update. The price target for Haleon's stock listed in Great Britain remains at 410 pence.
"In other recent news, Haleon plc reported significant earnings and revenue results, including a £230 million off-market share repurchase from Pfizer Inc. (NYSE:PFE) The consumer health company also increased its stake in the Chinese joint venture, Tianjin TSKF Pharmaceutical (TADAWUL:2070) Co. Ltd, to 88%, and finalized the divestment of its nicotine replacement therapy business to Dr. Reddy's Laboratories SA in a deal worth up to £500 million. Haleon's Chief Financial Officer, Dawn Allen, vested an award of Haleon Ordinary Shares and sold a portion to cover tax obligations, retaining a significant number of shares. Key changes to Haleon's board were also announced, with David Denton resigning as a Non-Executive Director and Bláthnaid Bergin stepping in as an independent Non-Executive Director. In terms of analyst ratings, Bernstein downgraded Haleon's stock from 'Outperform' to 'Market Perform', while Morgan Stanley maintained an Overweight rating, and Goldman Sachs downgraded Haleon's stock from "Buy" to "Neutral." Berenberg initiated coverage with a "Buy" rating. Two of Haleon's key executives, General Counsel Adrian Morris and Chief Marketing Officer Tamara Rogers (NYSE:ROG), acquired shares as part of the company's Share Reward Plan. These are all recent developments that have occurred with Haleon plc."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.